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Introduction
Autoinflammatory diseases (AD) are innate immune sys-
tem disorders, most of them with genetically identified
basis. Usual therapeutic approach until last decade
included non-steroidal antiinflamatories (NSAID), corti-
costeroids (CS) and colchicine. More recently, biological
therapies (BT) have proved to be useful for refractory
patients, especially those involving IL-1b blockade.
Objectives
To describe and analyze the experience with BT of a single
center cohort of adult patients diagnosed with autoinflam-
matory disorders, including familial Mediterranean fever
(FMF), TNF-receptor antagonist periodic syndrome
(TRAPS), Muckle-Wells syndrome (MWS), undefined per-
iodic fever (UPF), Blau syndrome (BS) and periodic fever,
aphtous stomatitis, pharyngitis and adenitis (PFAPA).
Methods
Clinical files of 30 adult patients diagnosed with AD fol-
lowed by the same clinical team of the Internal Medicine
Service of Vall Hebron hospital were reviewed. Demo-
graphic, clinical, laboratory, and therapeutic data prior and
after starting BT were collected. Data from BT treated
patients included: reason for prescription, drug, dosage,
treatment duration, response to treatment, tolerance and
adverse effects related to the drug.
Results
13 out of 30 patients (5 FMF, 1 TRAPS, 4 MWS, 1 UPF,
1 BS, 1 PFAPA) received BT: 7 patients (5 FMF, 1 BS,
1 TRAPS) received anti-TNF (6 etanercept 50 mg/weekly
SC, 1 patient adalimumab 40 mg/15 d SC) and 10 patients
(3 FMF, 4 MWS, 1 UPF, 1 BS, 1 PFAPA) received rIL-
1RA anakinra 100 mg/d SC. 4 patients (2 FMF, 1 BS,
1 UPF) received first etanercept and were switched to ana-
kinra due to incomplete / lack of response. Prescription
reasons for BT were: first option 5/13 patients (etanercept
for 1 TRAPS and anakinra for 4 MWS) and refractory
disease in 8/13 patients (anti-TNF: 4 FMF, 1 UPF, 1 BS;
anakinra: 3 FMF, 1 BS, 1 PFAPA, 1 UPF). Clinical
improvement defined as reduction in number and/or
intensity of attacks was achieved in 4/7 patients treated
with anti-TNF and in 9/10 patients receiving anakinra.
6 patients, all treated with anakinra, presented adverse
effects: 6 patients local erythema at punction site -2/6
were moderate reactions-, and 1 patient transient alopecia.
No opportunistic infection was detected.
Conclusion
Although BT are off-label indications in AD, its use has
to be considered a helpful and safe therapeutic alterna-
tive for refractory cases of FMF, UPF, BS or PFAPA. In
this serie, IL-1b blocking approach showed better
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